Early Diagnosis of Colorectal Cancer Based on a Non-invasive Metabolomics Profile
Launched by INSTITUT INVESTIGACIO SANITARIA PERE VIRGILI · Jun 5, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called EarlyCRC, is investigating whether certain substances found in urine and stool can help detect colorectal cancer and polyps early. The goal is to identify specific metabolites—small molecules that our bodies produce—that could easily and affordably distinguish between healthy individuals and those with colorectal cancer or polyps. This could lead to better and quicker diagnoses, improving treatment outcomes for patients.
To participate in this trial, you need to be between 18 and 80 years old and have a positive result from a stool test that checks for signs of colorectal cancer. However, if you have had another type of cancer in the last five years (except for certain skin cancers), severe kidney disease, or severe liver disease, you may not be eligible. If you join the study, you can expect to provide urine and stool samples, which will be analyzed to find the metabolites associated with colorectal cancer. Your participation could help advance research in this important area and potentially benefit future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with a positive FOBT test result from the Colorectal Cancer Early Detection Program and referred for a colonoscopy.
- Exclusion Criteria:
- • Patients diagnosed with another primary neoplasm in the last 5 years, with the exception of carcinoma in situ of the cervix or non-melanoma skin cancer.
- • Patients with severe kidney disease stage IV (creatinine clearance \< 30 ml/min).
- • Patients with severe active liver disease (hepatitis, cirrhosis).
- • Refusal to sign informed consent.
About Institut Investigacio Sanitaria Pere Virgili
Institut d'Investigació Sanitària Pere Virgili (IISPV) is a leading biomedical research institute based in Tarragona, Spain, dedicated to advancing health through innovative research and clinical trials. Affiliated with the University Rovira i Virgili and the Joan XXIII University Hospital, IISPV focuses on translating scientific discoveries into clinical applications to improve patient care. With a multidisciplinary team of researchers and clinicians, the institute emphasizes collaboration and excellence in various fields, including oncology, cardiovascular health, and infectious diseases. IISPV's commitment to fostering research innovation and enhancing healthcare outcomes positions it as a key player in the global scientific community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Reus, Tarragona, Spain
Tarragona, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported